You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. RNA aptamers for rapid response to COVID-19 variants

    SBC: DOTQUANT LLC            Topic: CDC

    ABSTRACT The COVID-19 pandemic caused by SARS-CoV-2 viruses has had an unprecedented disruptive global impact. Although vaccination has been expected to end the spread, the fast mutations have increased the breakthrough infection rates in the fully vaccinated population. RNA viruses are known to have very high rates of mutation and evolution. The high rate of mutation is correlated with virulence ...

    SBIR Phase I 2023 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. Chromosomal aberration detection in FFPE tissue using proximity ligation sequencing

    SBC: PHASE GENOMICS, INC.            Topic: NCI

    ABSTRACT The detection of chromosomal aberrations is a frontline diagnostic for the spectrum of blood neoplasms. Chromosomal aberrations, such as translocations, inversions, deletions and insertions, have been historically identified using cytogenetic methods or more recently through application of long read sequencing or optical mapping technologies. These methods have been less applicable in sol ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Non-invasively extendable megaprosthesis

    SBC: Granite Medical, LLC            Topic: NIAMS

    ABSTRACT This project is the development of a non-invasively extending distal femur replacement (DFR) for children and adolescents subsequent to bone tumor resection. Each year in the US there are 200-250 malignant bone tumor diagnoses in the distal femurs of patients 15 years and younger. With advances in chemotherapy, limb salvage surgery utilizing a megaprosthesis has increasingly become the tr ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Dialysate regeneration system based on photo-electrochemical urea oxidation and reactive adsorption to enable portable hemodialysis

    SBC: KULEANA TECHNOLOGY, INC.            Topic: 400

    PROJECT SUMMARY/ ABSTRACT Currently in the US there are over 400,000 kidney patients on dialysis. The primary therapy mode is hemodialysis and is performed in a hospital or private clinic. Current dialysis therapy requires a large device that must be continuously connected to a reverse osmosis (RO) system. A single treatment will require over 150L of AAMI dialysate making portable device unattaina ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Novel diagnostic biomarker reference standards for newborn screening of Mucopolysaccharidoses type I and II.

    SBC: GELBCHEM, LLC            Topic: NICHD

    Project Summary The goal of this project is to design and prepare diagnostic biomarker reference standards for the endogenous glycosaminoglycan (GAG) Mucopolysaccharidosis type I (MPS-I) and type II (MPS- II) biomarkers. MPS-I and MPS-II are lysosomal storage disorders (LSDs) which are listed on the Recommended Uniform Screening Panel (RUSP) in the United States and are included in global Newborn ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma.

    SBC: ORLANCE, INC            Topic: NCI

    PROJECT SUMMARY Orlance has developed a next-generation Gene Gun (MACH-1 GG) that efficiently delivers DNA and RNA into epidermal cells, leading to robust immune responses. Sequencing of tumors from individual patients has led to the identification of personalized neoantigens that could be targeted with cancer vaccines. However, technologies that can effectively deliver these cancer neoantigens an ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Ultrasound-coupled Electrical Impedance Tomography for Sarcopenia Assessment

    SBC: RYTEK MEDICAL INC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT Clinical Need: The coming decades promise a revolution in the personalized treatment for patients with breast cancer, including approaches to minimize collateral damage of curative. However, to help facilitate this, the academic and industrial clinical research communities need improved diagnostic biomarkers to assess the presence of muscle diseases such as sarcopenia. Onc ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins

    SBC: TALUS BIOSCIENCE INC            Topic: 400

    SUMMARY To evaluate how a drug candidate affects cells, researchers often study how the abundance or behavior of a specific set of proteins is changed by treatment with each compound. However, it is not currently possible to test the effect of every possible drug compound (rt500,000) on every human protein (~20,000) in hundreds of different types of cells. Even the most advanced protein analysis s ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke

    SBC: CELDARA MEDICAL, LLC            Topic: 105

    Project Summary Acute ischemic stroke (AIS) impacts 795,000 Americans per year, leaving 90% of patients with chronic disability. Prevalent cases of AIS in the US were estimated at 6.7M in 2017, translating to 6M Americans living with permanent stroke-related disability. AIS is characterized by cerebrovascular blockage that results in the formation of a central infarct with a surrounding ischemic p ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Modulation of Protein S-nitrosylation Signaling as a Potential Therapeutic Breakthrough in Rheumatoid Arthritis

    SBC: GSNO THERAPEUTICS, INC.            Topic: NIAMS

    PROJECT SUMMARY Rheumatoid arthritis (RA) is a prevalent autoimmune disease of the joints that involves autoimmunity, B and T cell infiltration, mitochondrial dysfunction, ECM degradation, oxidative stress and inflammation, that ultimately lead to cartilage destruction and bone reabsorption. Oxidative stress is a hallmark of RA: reactive oxygen species (ROS) inflict direct damage via the oxidation ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government